{"id":36327,"date":"2025-07-22T15:04:46","date_gmt":"2025-07-22T12:04:46","guid":{"rendered":"https:\/\/massivebio.com\/?p=36327"},"modified":"2025-07-22T15:06:08","modified_gmt":"2025-07-22T12:06:08","slug":"multiple-myeloma-prognosis-by-age-how-it-changes-over-time","status":"publish","type":"post","link":"https:\/\/massivebio.com\/multiple-myeloma-prognosis-by-age-how-it-changes-over-time\/","title":{"rendered":"Multiple Myeloma Prognosis by Age: How It Changes Over Time"},"content":{"rendered":"<section class=\"l-section wpb_row height_small\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_grid cols_1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><h2><span style=\"font-weight: 400;\">Multiple Myeloma Prognosis by Age: How It Changes Over Time<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Multiple myeloma is a rare but serious blood cancer that begins in the plasma cells of the bone marrow. These cells are part of your immune system and are responsible for producing antibodies to help fight infection. A common question is <\/span><a href=\"https:\/\/massivebio.com\/what-is-multiple-myeloma\/\"><span style=\"font-weight: 400;\">What is multiple myeloma?<\/span><\/a><span style=\"font-weight: 400;\"> In multiple myeloma, abnormal plasma cells grow uncontrollably, interfering with the production of healthy blood cells and leading to various complications, including bone damage, anemia, kidney problems, and frequent infections.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Like many cancers, the prognosis for multiple myeloma\u2014which refers to the likely outcome or course of the disease\u2014varies significantly based on several factors. Among the most influential is age. <\/span><a href=\"https:\/\/massivebio.com\/understanding-multiple-myeloma-prognosis\/\"><span style=\"font-weight: 400;\">Understanding multiple myeloma prognosis<\/span><\/a><span style=\"font-weight: 400;\"> by age changes over time is essential not only for patients but also for caregivers and loved ones seeking clarity and guidance.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Survival rates, life expectancy, and treatment outcomes vary depending on age. Whether researching the average age for multiple myeloma or understanding <\/span><b>life expectancy for multiple myeloma at age 70<\/b><span style=\"font-weight: 400;\"> or 80, all information is presented clearly and compassionately.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">Why Is Age of Onset Important in Understanding Multiple Myeloma?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Unlike some types of cancer that usually affect younger adults, multiple myeloma is generally considered a disease that affects older adults, so age of onset is important. The <\/span><b>multiple myeloma age of onset<\/b><span style=\"font-weight: 400;\"> is a key factor in understanding the disease\u2019s behavior.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Average Age for Multiple Myeloma<\/span><\/p>\n<p><span style=\"font-weight: 400;\">According to data from the American Cancer Society, the average age for multiple myeloma diagnosis is around 69 to 70 years old. The condition is rarely seen in people under 40, and only a small percentage of cases occur in individuals under 50.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This age pattern matters because older <\/span><a href=\"https:\/\/massivebio.com\/patients\/\"><span style=\"font-weight: 400;\">patients <\/span><\/a><span style=\"font-weight: 400;\">often have other age-related health conditions\u2014such as heart disease, kidney impairment, or reduced bone density\u2014that can complicate both the disease and its treatment.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Most Affected Age Groups<\/span><\/h3>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Multiple myeloma age group <\/b><span style=\"font-weight: 400;\">65\u201374: The most commonly diagnosed segment.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Multiple myeloma at age 80<\/b><span style=\"font-weight: 400;\"> and above: Less common, but prognosis is typically more cautious due to frailty and comorbidities.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Multiple myeloma after age 75: Still treatable, but may require modified, less aggressive therapy.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Recognizing the typical <\/span><b>multiple myeloma age range<\/b><span style=\"font-weight: 400;\"> helps in identifying high-risk individuals and initiating screening when appropriate.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">How Age Affects Prognosis and Treatment Options?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">It affects the body\u2019s ability to handle aggressive treatments such as chemotherapy or stem cell transplants and plays a role in how quickly the disease may progress. As a result, treatment plans are often adjusted based on a patient\u2019s age and overall health status\u2014not just their diagnosis. The<\/span><b> multiple myeloma prognosis by age<\/b><span style=\"font-weight: 400;\"> reflects more than just chronological numbers.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Younger Patients (Under 65)<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Patients diagnosed before 65 tend to have:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Better overall health<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Fewer comorbidities<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Stronger immune response<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Greater eligibility for aggressive treatments, such as autologous stem cell transplant (ASCT)<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">These factors usually lead to a more favorable prognosis, with survival rates exceeding 8 to 10 years in many cases, especially if caught early and treated effectively.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Middle-Aged Patients (65\u201374)<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">In this group, which includes the <\/span><b>average age for multiple myeloma<\/b><span style=\"font-weight: 400;\">, outcomes are still promising, especially for patients who maintain good overall health.<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Many are still candidates for stem cell transplants<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Newer drugs and therapies are effective at extending remission<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Survival rates vary but often range from 5 to 8 years, depending on stage and treatment response<\/span><\/li>\n<\/ul>\n<h3><span style=\"font-weight: 400;\">Older Adults (75+)<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">When looking at <\/span><b>multiple myeloma after age 75<\/b><span style=\"font-weight: 400;\">, treatment decisions become more complex:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Comorbidities may limit treatment options<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Reduced bone marrow reserve affects recovery from chemotherapy<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Risk of treatment-related complications increases<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Still, treatment is not ruled out. Many patients in their 70s and 80s experience benefits from personalized treatment plans. For instance, life expectancy for multiple myeloma at age 70 may still exceed 3\u20135 years with effective treatment, and some older patients experience meaningful remissions.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">What is the Multiple Myeloma Survival Rate by Age?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Multiple myeloma survival rates decrease with age about 60\u201370% under 65, 50\u201355% for ages 65\u201374, and 35\u201340% for 75 and older. Survival is typically measured using the five-year survival rate, a standard metric for evaluating cancer outcomes. According to the SEER (Surveillance, Epidemiology, and End Results) Program:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Under age 65: 5-year survival rate is approximately 60\u201370%, depending on the stage and treatment<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Ages 65\u201374: Survival drops slightly to around 50\u201355%<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Age 75 and older: 5-year survival declines to about 35\u201340%<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">These numbers reflect average outcomes, not individual predictions. Some older adults live well beyond five years, especially with newer treatments such as immunotherapy, proteasome inhibitors, and monoclonal antibodies.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">It\u2019s also important to consider the biological age\u2014a measure of one\u2019s overall physical and medical health\u2014which can be more relevant than the number on a birth certificate.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">What is Life Expectancy Based on Age and Treatment Progression?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">While life expectancy at age 70 is generally 4-6+ years, when focusing on quality of life at age 80, the average is 2-4 years.When discussing <\/span><b>multiple myeloma life expectancy by age<\/b><span style=\"font-weight: 400;\">, context is everything. Life expectancy depends not only on the patient\u2019s age but also on the stage of the disease, genetic risk factors, overall health, and treatment response.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Life Expectancy for Multiple Myeloma at Age 70<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">For a generally healthy 70-year-old diagnosed with early-stage disease and access to modern therapies:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Expected life span can be 4\u20136 years or longer<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Some patients live 10+ years with ongoing maintenance therapy<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Quality of life is often well-preserved during remission phases<\/span><\/li>\n<\/ul>\n<h3><span style=\"font-weight: 400;\">Multiple Myeloma at Age 80<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">In patients 80 and older, treatment goals often shift from aggressive cures to disease control and symptom relief.<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Life expectancy averages 2\u20134 years, depending on health status<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Frailty, cognitive function, and kidney performance affect prognosis<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Therapy focuses on improving quality of life rather than extending it at all costs<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Despite a more conservative approach, age should not automatically exclude patients from active treatment. Recent studies show that selected patients over 80 do benefit from low-dose chemotherapy and newer targeted treatments.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">What Does the Future Hold for Age-Based Myeloma Treatment?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">The future of age-based myeloma treatment is promising, with ongoing advancements making the disease more manageable and improving survival rates for patients of all ages. Advancements in treatment continue to improve the <\/span><b>multiple myeloma survival rate by age<\/b><span style=\"font-weight: 400;\">. What once was considered an incurable cancer with a bleak outlook is now a chronic, manageable disease for many, including older adults.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Emerging Trends<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Targeted therapies: These are more effective and better tolerated than traditional chemotherapy<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">CAR-T cell therapy: Still mostly for younger patients but shows promise for future use in older populations<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Minimal residual disease (MRD) tracking: Helps doctors adjust treatment based on how well the cancer responds<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Telemedicine and home infusions: Help older patients access care with fewer hospital visits<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">In the coming years, age-specific treatment protocols and expanded access to clinical trials for elderly patients may become more common.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Multiple myeloma is a complex disease, and age plays a pivotal role in how it progresses and how it\u2019s treated. From the multiple myeloma age of onset in the late 60s to concerns about multiple myeloma at age 80, the spectrum is wide\u2014but not hopeless.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Knowing how age affects multiple myeloma prognosis helps patients and families make informed choices. Whether you&#8217;re newly diagnosed at 70, supporting a parent with multiple myeloma after age 75, or wondering about your own risk, personalized care and early action remain the best tools.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Thanks to evolving therapies, people with multiple myeloma\u2014young and old alike\u2014can live longer, healthier, and more fulfilling lives than ever before. Massive Bio is reshaping cancer care by offering innovative, patient-focused solutions that promote smarter treatments and equal access.<\/span><\/p>\n<p><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4077086\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4077086\/<\/span><\/a><\/p>\n<p><a href=\"https:\/\/www.medicalnewstoday.com\/articles\/multiple-myeloma-prognosis-by-age\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">https:\/\/www.medicalnewstoday.com\/articles\/multiple-myeloma-prognosis-by-age<\/span><\/a><span style=\"font-weight: 400;\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.polygonhealth.app\/post\/multiple-myeloma-prognosis-by-age-what-you-need-to-know\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">https:\/\/www.polygonhealth.app\/post\/multiple-myeloma-prognosis-by-age-what-you-need-to-know<\/span><\/a><span style=\"font-weight: 400;\">\u00a0\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/section>\n","protected":false},"excerpt":{"rendered":"Multiple Myeloma Prognosis by Age: How It Changes Over Time Multiple myeloma is a rare but serious blood cancer that begins in the plasma cells of the bone marrow. These cells are part of your immune system and are responsible for producing antibodies to help fight infection. A common question is What is multiple myeloma?...","protected":false},"author":11,"featured_media":36328,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[57],"tags":[],"class_list":["post-36327","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.6 (Yoast SEO v26.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Multiple Myeloma Prognosis by Age: How It Changes Over Time<\/title>\n<meta name=\"description\" content=\"Multiple myeloma is a rare but serious blood cancer that begins in the plasma cells of the bone marrow.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/massivebio.com\/multiple-myeloma-prognosis-by-age-how-it-changes-over-time\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Multiple Myeloma Prognosis by Age: How It Changes Over Time %\" \/>\n<meta property=\"og:description\" content=\"Multiple myeloma is a rare but serious blood cancer that begins in the plasma cells of the bone marrow.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/massivebio.com\/multiple-myeloma-prognosis-by-age-how-it-changes-over-time\/\" \/>\n<meta property=\"og:site_name\" content=\"Massive Bio\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-22T12:04:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-22T12:06:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/07\/Multiple-Myeloma-Prognosis-by-Age_-How-It-Changes-Over-Time-4.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"767\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sinan Gul\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MassiveBio\" \/>\n<meta name=\"twitter:site\" content=\"@MassiveBio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sinan Gul\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Multiple Myeloma Prognosis by Age: How It Changes Over Time","description":"Multiple myeloma is a rare but serious blood cancer that begins in the plasma cells of the bone marrow.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/massivebio.com\/multiple-myeloma-prognosis-by-age-how-it-changes-over-time\/","og_locale":"en_US","og_type":"article","og_title":"Multiple Myeloma Prognosis by Age: How It Changes Over Time %","og_description":"Multiple myeloma is a rare but serious blood cancer that begins in the plasma cells of the bone marrow.","og_url":"https:\/\/massivebio.com\/multiple-myeloma-prognosis-by-age-how-it-changes-over-time\/","og_site_name":"Massive Bio","article_publisher":"https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/","article_published_time":"2025-07-22T12:04:46+00:00","article_modified_time":"2025-07-22T12:06:08+00:00","og_image":[{"width":1024,"height":767,"url":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/07\/Multiple-Myeloma-Prognosis-by-Age_-How-It-Changes-Over-Time-4.webp","type":"image\/webp"}],"author":"Sinan Gul","twitter_card":"summary_large_image","twitter_creator":"@MassiveBio","twitter_site":"@MassiveBio","twitter_misc":{"Written by":"Sinan Gul","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/massivebio.com\/multiple-myeloma-prognosis-by-age-how-it-changes-over-time\/#article","isPartOf":{"@id":"https:\/\/massivebio.com\/multiple-myeloma-prognosis-by-age-how-it-changes-over-time\/"},"author":{"name":"Sinan Gul","@id":"https:\/\/massivebio.com\/#\/schema\/person\/961d749445523a588f7ffb7086d037c6"},"headline":"Multiple Myeloma Prognosis by Age: How It Changes Over Time","datePublished":"2025-07-22T12:04:46+00:00","dateModified":"2025-07-22T12:06:08+00:00","mainEntityOfPage":{"@id":"https:\/\/massivebio.com\/multiple-myeloma-prognosis-by-age-how-it-changes-over-time\/"},"wordCount":1278,"commentCount":0,"publisher":{"@id":"https:\/\/massivebio.com\/#organization"},"image":{"@id":"https:\/\/massivebio.com\/multiple-myeloma-prognosis-by-age-how-it-changes-over-time\/#primaryimage"},"thumbnailUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/07\/Multiple-Myeloma-Prognosis-by-Age_-How-It-Changes-Over-Time-4.webp","articleSection":["Blog"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/massivebio.com\/multiple-myeloma-prognosis-by-age-how-it-changes-over-time\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/massivebio.com\/multiple-myeloma-prognosis-by-age-how-it-changes-over-time\/","url":"https:\/\/massivebio.com\/multiple-myeloma-prognosis-by-age-how-it-changes-over-time\/","name":"Multiple Myeloma Prognosis by Age: How It Changes Over Time","isPartOf":{"@id":"https:\/\/massivebio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/massivebio.com\/multiple-myeloma-prognosis-by-age-how-it-changes-over-time\/#primaryimage"},"image":{"@id":"https:\/\/massivebio.com\/multiple-myeloma-prognosis-by-age-how-it-changes-over-time\/#primaryimage"},"thumbnailUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/07\/Multiple-Myeloma-Prognosis-by-Age_-How-It-Changes-Over-Time-4.webp","datePublished":"2025-07-22T12:04:46+00:00","dateModified":"2025-07-22T12:06:08+00:00","description":"Multiple myeloma is a rare but serious blood cancer that begins in the plasma cells of the bone marrow.","breadcrumb":{"@id":"https:\/\/massivebio.com\/multiple-myeloma-prognosis-by-age-how-it-changes-over-time\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/massivebio.com\/multiple-myeloma-prognosis-by-age-how-it-changes-over-time\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/massivebio.com\/multiple-myeloma-prognosis-by-age-how-it-changes-over-time\/#primaryimage","url":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/07\/Multiple-Myeloma-Prognosis-by-Age_-How-It-Changes-Over-Time-4.webp","contentUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/07\/Multiple-Myeloma-Prognosis-by-Age_-How-It-Changes-Over-Time-4.webp","width":1024,"height":767,"caption":"Multiple Myeloma Prognosis by Age How It Changes Over Time 4"},{"@type":"BreadcrumbList","@id":"https:\/\/massivebio.com\/multiple-myeloma-prognosis-by-age-how-it-changes-over-time\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Homepage","item":"https:\/\/massivebio.com\/"},{"@type":"ListItem","position":2,"name":"Blog","item":"https:\/\/massivebio.com\/blog-en\/"},{"@type":"ListItem","position":3,"name":"Multiple Myeloma Prognosis by Age: How It Changes Over Time"}]},{"@type":"WebSite","@id":"https:\/\/massivebio.com\/#website","url":"https:\/\/massivebio.com\/","name":"Cancer Analysis and Clinical Trial Matching","description":"Best Oncology Advisory Services By Cancer Treatment Care Specialists &amp; Tumor Board Experts in America","publisher":{"@id":"https:\/\/massivebio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/massivebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/massivebio.com\/#organization","name":"Massive Bio","url":"https:\/\/massivebio.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/massivebio.com\/#\/schema\/logo\/image\/","url":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/01\/Massive-Bio-Logo-Circle.svg","contentUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/01\/Massive-Bio-Logo-Circle.svg","width":"1024","height":"1024","caption":"Massive Bio"},"image":{"@id":"https:\/\/massivebio.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/","https:\/\/x.com\/MassiveBio","https:\/\/instagram.com\/massive_bio\/","https:\/\/tiktok.com\/@massivebio","https:\/\/youtube.com\/massivebio"],"email":"support@massivebio.com","legalName":"Massive Bio"},{"@type":"Person","@id":"https:\/\/massivebio.com\/#\/schema\/person\/961d749445523a588f7ffb7086d037c6","name":"Sinan Gul"}]}},"_links":{"self":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/36327","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/comments?post=36327"}],"version-history":[{"count":2,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/36327\/revisions"}],"predecessor-version":[{"id":36330,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/36327\/revisions\/36330"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/media\/36328"}],"wp:attachment":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/media?parent=36327"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/categories?post=36327"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/tags?post=36327"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}